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Abstract63
The subset of patients who develop critical illness in Covid-19 have extensive inflammation affecting the lungs164
and are strikingly different from other patients: immunosuppressive therapy benefits critically-ill patients, but65
may harm some non-critical cases.2 Since susceptibility to life-threatening infections and immune-mediated66
diseases are both strongly heritable traits, we reasoned that host genetic variation may identify mechanistic67
targets for therapeutic development in Covid-19.368
GenOMICC (Genetics Of Mortality In Critical Care, genomicc.org) is a global collaborative study to un-69
derstand the genetic basis of critical illness. Here we report the results of a genome-wide association study70
(GWAS) in 2244 critically-ill Covid-19 patients from 208 UK intensive care units (ICUs), representing >95%71
of all ICU beds. Ancestry-matched controls were drawn from the UK Biobank population study and results72
were confirmed in GWAS comparisons with two other population control groups: the 100,000 genomes project73
and Generation Scotland.74
We identify and replicate three novel genome-wide significant associations, at chr19p13.3 (rs2109069, p =75
3.98 × 10-12), within the gene encoding dipeptidyl peptidase 9 (DPP9), at chr12q24.13 (rs10735079, p =76
1.65 × 10-8) in a gene cluster encoding antiviral restriction enzyme activators (OAS1, OAS2, OAS3), and77
at chr21q22.1 (rs2236757, p = 4.99 × 10-8) in the interferon receptor gene IFNAR2. Consistent with our78
focus on extreme disease in younger patients with less comorbidity, we detect a stronger signal at the known79
3p21.31 locus than previous studies (rs73064425, p = 4.77 × 10-30).80
We identify potential targets for repurposing of licensed medications. Using Mendelian randomisation we81
found evidence in support of a causal link from low expression of IFNAR2, and high expression of TYK2, to82
life-threatening disease. Transcriptome-wide association in lung tissue revealed that high expression of the83
monocyte/macrophage chemotactic receptor CCR2 is associated with severe Covid-19.84
Our results identify robust genetic signals relating to key host antiviral defence mechanisms, and mediators85
of inflammatory organ damage in Covid-19. Both mechanisms may be amenable to targeted treatment with86
existing drugs. Large-scale randomised clinical trials will be essential before any change to clinical practice.87
Introduction88
Critical illness in Covid-19 is caused, in part, by inflammatory injury affecting the lungs and lung blood89
vessels.4,5 There are therefore at least two distinct biological components to mortality risk: susceptibility to90
viral infection, and propensity to develop harmful pulmonary inflammation. Susceptibility to life-threatening91
infections6 and immune-mediated diseases are both strongly heritable. In particular, susceptibility to respi-92
ratory viruses7 such as influenza8 is heritable and known to be associated with specific genetic variants.9 In93
Covid-19, one genetic locus, 3p21.31 has been repeatedly associated with hospitalisation.10,11 As with other94
viral illnesses,12 there are several examples of loss-of-function variants affecting essential immune processes95
that lead to severe disease in young people: for example TLR7 defects among 4 cases with severe disease.1396
Understanding the molecular mechanisms of critical illness in Covid-19 may reveal new therapeutic targets97
to modulate this host immune response to promote survival.398
There is now strong evidence that critical illness caused by Covid-19 is qualitatively different from mild99
or moderate disease, even among hospitalised patients. There are multiple distinct disease phenotypes with100
differing patterns of presenting symptoms14 and marked differential responses to immunosuppressive therapy.2101
In patients without respiratory failure, there is a trend towards harm from treatment with corticosteroids,102
whereas among patients with critical respiratory failure, there is a very substantial benefit.2 On this basis,103
we can consider patients with critical Covid-19 respiratory failure to have distinct pathophysiology.104
In the UK, the group of patients admitted to critical care is relatively homogeneous, with profound hypox-105
aemic respiratory failure being the archetypal presentation.15 The active disease process in these patients106
is strikingly responsive to corticosteroid therapy16 and is characterised by pulmonary inflammation includ-107
ing diffuse alveolar damage, macrophage/monocyte influx, mononuclear cell pulmonary artery vasculitis and108
microthrombus formation.4,5109
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Host-directed therapies have long been an aspiration for the treatment of severe disease caused by respiratory110
viruses.17 Identification of genetic loci associated with susceptibility to Covid-19 may lead to specific targets111
for repurposing or drug development.3112
The GenOMICC (Genetics Of Mortality In Critical Care, genomicc.org) study has been recruiting patients113
with critical illness syndromes, including influenza, sepsis, and emerging infections, for 5 years. GenOMICC114
works in partnership with Genomics England to study Covid-19. In order to better understand the host115
mechanisms leading to life-threatening Covid-19, we performed a genome-wide association study comparing116
to controls from population genetic studies in the UK.117
Results118
Critically-ill cases were recruited through the GenOMICC study in 208 UK Intensive Care Units and hospi-119
talised cases through the International Severe Acute Respiratory Infection Consortium (ISARIC) Coronavirus120
Clinical Characterisation Consortium (4C) study. Demographic and summary clinical characteristics of the121
cohort are described in Table 1. Cases were representative of the UK critically-ill population.15122
Table 1: Baseline characteristics of patients included. Significant comorbidity was defined as the presence of
functionally-limiting comorbid illness in GenOMICC, in the assessment of the treating clinicians. In ISARIC
4C significant comorbidity refers to the presence of any chronic cardiac, lung, kidney, or liver disease, cancer
or dementia. Age is shown as mean ± standard deviation.
Patient Characteristics GenOMICC (n=2109) ISARIC 4C (n=134)
missing data missing data
Female sex 624 (30%) 46 (34%)
Age (yrs, mean ± SD) 57.3 ± 12.1 57.3 ± 2.9
European ancestry 1573 (75%) 103 (76%)
South Asian ancestry 219 (10%) 18 (13%)
African ancestry 174 (8%) 8 (6%)
East Asian ancestry 143 (7%) 6 (4%)
Significant comorbidity 396 (19%) 49 (2%) 42 (28%) 31 (21%)
Invasive ventilation 1557 (74%) 35 (2%) 25 (19%) 31 (23%)
Died (60 days) 459 (22%) 338 (16%) 22 (16%) 30 (22%)
DNA was extracted from whole blood and genome-wide genotyping and quality control were performed123
according to standard protocols (Materials & Methods). Briefly, genetic ancestry was inferred for unrelated124
individuals passing quality control using ADMIXTURE and reference individuals from the 1000 Genomes125
project. Imputation was performed using the TOPMed reference panel.18 Whole genome sequencing was126
performed on a subset of 1613 cases, and used to confirm both array-genotyped and imputed genotypes.127
From the 4469187 imputed variants that passed all filters after GWAS, 72658 did not pass QC filtering in128
WGS data and were removed. Comparing the allele frequencies of each SNP between WGS and imputation,129
the correlation of allele frequencies was r2=0.9994. All variants with a difference of > 5% were removed from130
the analysis, leaving 4396207 imputed variants.131
Ancestry-matched controls not having Covid-19 PCR tests were selected from the large population-based132
cohort UK Biobank in a ratio of 5 controls to 1 case. GWAS was carried out separately by ancestry group133
using logistic regression in PLINK and accounting for age, sex, postal code deprivation decile and principal134
components of ancestry. As well as standard filters for minor allele frequency (>0.01), imputation quality135
(0.9) and Hardy-Weinberg equilibrium (10-50^), GWAS results were filtered on allele frequency against the136
genome aggregation database (gnomAD), to avoid biases arising from different imputation panels (and arrays)137
between cases and controls. The largest ancestry group contained 1676 individuals of European descent138
(EUR).139
Following linkage disequilibrium-based clumping, 15 independent association signals were genome-wide sig-140
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nificant at p < 5 × 10-8. Eight of these were successfully validated using a GWAS using two independent141




Figure 1: Summary of GWAS results for EUR ancestry group in GenOMICC. a. Manhattan plot showing
SNP-level p-values for genome-wide significant associations in largest ancestry group, EUR (red horizontal
line shows genome-wide significance at −𝑙𝑜𝑔10(5𝑥10−8)) b-d. Locuszoom19 plots showing genomic regions
around protein-coding genes. e. Quantile-quantile (QQ) plot.
GWAS results143
Table 2: Lead variants from independent genome-wide significant regions. Full summary statistics are pro-
vided in Supplementary Information. chr:pos - chromosome and position of the top SNP (build 37); Risk –
risk allele; Other - other allele; RAF - risk allele frequency; OR - effect size (odds ratio) of the risk allele;
locus – gene nearest to the top SNP.
SNP chr:pos(b37) Risk Other RAF OR P Locus
rs73064425 3:45901089 T C 0.08 2.14 4.77 x 10-30 LZTFL1
rs9380142 6:29798794 A G 0.70 1.30 3.23 x 10-8 HLA-G
rs143334143 6:31121426 A G 0.079 1.85 8.82 x 10-18 CCHCR1
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SNP chr:pos(b37) Risk Other RAF OR P Locus
rs3131294 6:32180146 G A 0.87 1.45 2.81 x 10-8 NOTCH4
rs10735079 12:113380008 A G 0.64 1.29 1.65 x 10-8 OAS3
rs74956615 19:10427721 A T 0.06 1.59 2.31 x 10-8 ICAM5/TYK2
rs2109069 19:4719443 A G 0.33 1.36 3.98 x 10-12 DPP9
rs2236757 21:34624917 A G 0.29 1.28 5.00 x 10-8 IFNAR2
Since no study of critical illness in Covid-19 of sufficient size is available, replication was sought in the Covid-144
19 Host Genetics Initiative (HGI) hospitalised COVID-19 versus population analysis, with UK Biobank cases145
excluded. In addition to the locus on chr3 already reported (rs73064425, OR=2.14, discovery p=4.77 ×146
10-30), we found robust replication for the novel associations in three loci from GenOMICC: a locus on chr12147
in the OAS gene cluster (rs74956615, OR=1.59, discovery p= 1.65 × 10-8) and in DPP9 on chr19 (rs2109069,148
OR=1.36, discovery p=3.98 × 10-12) and locus on chromosome 21, containing gene IFNAR2 (rs2236757,149
OR=1.28, p=5 × 10-8) (Table 3).150
Replication151
Table 3: Replication in external data from Covid-19 HGI. chr:pos - chromosome and position of the top SNP
(build 37); Risk – risk allele; Other - other allele; beta - effect size of the risk allele; OR - odds ratio; locus –
gene nearest to the top SNP; gcc.eur - GenOMICC study, European ancestry; hgi - Covid-19 human genetics
initiative; * Bonferroni significant.
SNP chr:pos (b37) Risk Other beta gcc.eur P gcc.eur beta hgi P hgi Locus
rs73064425 3:45901089 T C 0.76 4.8 x 10-30 0.53 1.6 x 10-12* LZTFL1
rs9380142 6:29798794 A G 0.26 3.2 x 10-8 0.036 0.46 HLA-G
rs143334143 6:31121426 A G 0.62 8.8 x 10-18 0.064 0.34 CCHCR1
rs3131294 6:32180146 G A 0.38 2.8 x 10-8 0.1 0.2 NOTCH4
rs10735079 12:113380008 A G 0.26 1.6 x 10-8 0.14 0.0027* OAS3
rs2109069 19:4719443 A G 0.31 4 x 10-12 0.17 0.00031* DPP9
rs74956615 19:10427721 A T 0.46 2.3 x 10-8 0.14 0.4 ICAM5/TYK2
rs2236757 21:34624917 A G 0.25 5 x 10-8 0.18 0.00016* IFNAR2
To further increase power for exploratory downstream analyses meta-analysis of GENOMICC and HGI was152
performed using inverse-variance meta-analysis in METAL,20 discovering 2 additional loci, one on chromo-153
some 8, near HAS2 (rs10087754, OR=1.19, meta-analysis p = 3.1 × 10-8) and another on chromosome 19,154
near TYK2 (rs11085727, OR=1.25, p = 1.57 × 10-10) (Table 4).155
Table 4: Meta-analysis of GenOMICC (EUR) and HGI hospitalized covid vs. population studies. SNP – the
strongest SNP in the locus, ; A1 – effect allele; A2 - alternative allele; beta - effect size of the effect allele;
nearest gene – gene nearest to the top SNP.
SNP A1 A2 beta eur p eur beta hgi.meta OR hgi.meta p hgi.meta Gene
rs67959919 A G 0.76 7.1 x 10-30 0.66 1.9 7.3 x 10-38 LZTFL1
rs143334143 A G 0.62 8.8 x 10-18 0.31 1.4 7 x 10-10 CCHCR1
rs9501257 G A 0.49 1.1 x 10-11 0.31 1.4 3.8 x 10-9 HLA-DPB1
rs622568 C A 0.45 7.1 x 10-16 0.29 1.3 7 x 10-11 VSTM2A
rs10087754 T A 0.19 7.6 x 10-6 0.18 1.2 3.1 x 10-8 HAS2-ASI
rs10860891 C A 0.55 1.6 x 10-18 0.3 1.3 7.5 x 10-10 IGF1
rs4766664 G T 0.25 3.1 x 10-8 0.2 1.2 2.5 x 10-9 OAS1
rs2277732 A C 0.3 1.8 x 10-11 0.25 1.3 1.6 x 10-13 DPP9
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SNP A1 A2 beta eur p eur beta hgi.meta OR hgi.meta p hgi.meta Gene
rs11085727 T C 0.24 1.3 x 10-7 0.22 1.2 1.6 x 10-10 TYK2
rs13050728 T C 0.23 3 x 10-7 0.21 1.2 2.5 x 10-10 IFNAR2
Mendelian randomisation156
Mendelian randomisation provides evidence for a causal relationship between an exposure variable and an157
outcome, given a set of assumptions.21 We employ it here to assess the evidence in support of causal effects158
of RNA expression of various genes on the odds of critical Covid-19.159
We specified an a priori list of target genes that relate to the mechanism of action of many host-targeted drugs160
that have been proposed for the treatment of Covid-19 (Supp Table 1). Seven of these targets had a suitable161
locally-acting eQTL in GTEx(v7). Of these, IFNAR2 remained significant after Bonferroni correcting for162
multiple testing for 7 tests (beta -1.49, standard error 0.52, p-value 0.0043), with equivocal evidence of163
heterogeneity (HEIDI22 p-value = 0.0150; 0.05/7 < p-value < 0.05; 6 SNPs). This Mendelian randomisation164
result successfully replicated in the results of COVID19-hg (ANA_B2_V2; hospitalized covid vs. population;165
UK Biobank excluded): beta -1.37, standard error 0.51, p-value 0.0066 (1 test).166
We then performed transcriptome-wide Mendelian randomisation to quantify support for unselected genes167
as potential therapeutic targets. Instruments were available for 4,614 unique Ensembl gene IDs. No genes168
were statistically significant after correcting for multiple comparisons in this analysis (4,614 tests). After169
conservative filtering for heterogeneity (HEIDI p-value > 0.05), the smallest Mendelian randomisation p-170
value was 0.00049 for a variant at chr19:10466123 affecting expression of TYK2. 9 other genes with nominally171
significant Mendelian randomisation pvalues (p<0.005) were then tested for independent external evidence172
(Supplementary Information). We found that TYK2 had a significant independent Mendelian randomisation173
p = 0.0022 in this second set (Bonferroni-corrected significance threshold = 0.006). In both cases it should174
be noted that this is not a complete replication, because the same GTEx expression data was used for both175
analyses.176
TWAS177
We performed TWAS23,24 to link GWAS results to tissue-specific gene expression data by inferring gene178
expression from known genetic variants that are associated with transcript abundance (expression quantitative179
trait loci, eQTL). For this analysis we used GTExv8 data for two disease-relevant tissues chosen a priori:180
whole blood and lung(Figure 3), and performed a combined meta-TWAS analysis25 to detect predicted181
expression differences across both tissues.182
We discovered 18 genes with genome-wide significant differences in predicted expression compared to controls183
(Supplementary Information). This included 4 genes with differential predicted expression in lung tissue184
(Figure 3; 3 on chr3: CCR2, CCR3 and CXCR6, and 1 on chr5: MTA2B).185
Genetic correlations, tissue, and cell-type associations186
We tested for genetic correlations with other traits, that is the degree to which the underlying genetic187
components  are shared with severe Covid-19. Using the high-definition likelihood (HDL) method,26 we188
identified significant negative genetic correlations with educational attainment and intelligence. Significant189
positive genetic correlations were detected for a number of adiposity phenotypes including body mass index190
and leg fat, as well as pulse rate, neck/shoulder pain, thyroxine, and lansoprazole medications.191
Consistent with GWAS results from other infectious and inflammatory diseases,27 there was a significant192
enrichment of strongly-associated variants in promoters and enhancers, particularly those identified by the193
EXaC study as under strong evolutionary selection (Supplementary Information).28 The strongest tissue type194
enrichment was in spleen, followed by pancreas (Supplementary Information).195
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Figure 2: Detail of the TYK2 and IFNAR2 loci showing location of instrumental variables used for Mendelian
randomisation. x-axes: genomic position with gene locations marked; y-axes: GenOMICC GWAS -log10(p-
values); dashed line: genome-wide significance at −𝑙𝑜𝑔10(5𝑥10−8); blue triangles: variants used as the in-
strumental variables for MR, for TYK2 and IFNAR2, respectively. A detailed description of the method of
instrument selection is provided in Materials and Methods.
b.
Figure 3: Summary of TWAS results. a. Gene-level Manhattan plot showing results from meta-TWAS
analysis across tissues. b. z-scores showing direction of effect for genotype-inferred expression of transcripts
encoding protein-coding genes in lung tissue (GTEXv8). Red highlighting indicates genome-wide significance
at p < 5 × 10-6.
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Discussion196
We have discovered and replicated significant genetic associations with life-threatening Covid-19 (Figure 1).197
Our focus on critical illness increases the probability that some of these associations relate to the later,198
immune-mediated disease associated with respiratory failure requiring invasive mechanical ventilation.2 Im-199
portantly, the GWAS approach is unbiased and genome-wide, enabling the discovery of completely new patho-200
physiological mechanisms. Because genetic variation can be used to draw a causal inference, genetic evidence201
in support of a therapeutic target substantially improves the probability of successful drug development.29202
In particular, Mendelian randomisation occupies a uinque position in the hierarchy of clinical evidence.30203
Patients admitted to intensive care units in the UK during the first wave of Covid-19 were, on average, younger204
and less burdened by comorbid illness than the hospitalised population.15 Compared to other countries, UK205
ICU admission tends to occur at a higher level of illness severity,31 reflected in the high rate of invasive206
mechanical ventilation use in our cohort (73%; Table 1). Therefore, the population studied here are defined207
by their propensity to critical respiratory failure due to Covid-19. GenOMICC recruited in 208 intensive208
care units (covering more than 95% of UK ICU capacity), ensuring that a broad spread across the genetic209
ancestry of UK patients was included (Supplementary Information).210
For external replication, the nearest comparison is the hospitalised vs population analysis in the Covid-19211
Host Genetics initiative, which has been generously shared with the international community. Likewise, full212
summary statistics from GenOMICC are openly available in order to advance the rate of discovery.213
Despite the differences in case definitions, novel associations from our study of critical illness replicate robustly214
in the hospitalised case study(Table 3). Separately, the Mendelian randomisation results implying a causal215
role for IFNAR2 and TYK2 are also statistically significant in this cohort. Our findings reveal that critical216
illness in Covid-19 is related to at two biological mechanisms: innate antiviral defences, which are known to217
be important early in disease (IFNAR2 and OAS genes), and host-driven inflammatory lung injury, which is218
a key mechanism of late, life-threatening Covid-19 (DPP9, TYK2 and CCR2).2219
Interferons are canonical host antiviral signalling mediators, and stimulate release of many essential compo-220
nents of the early host response to viral infection.32 Consistent with a beneficial role for type I interferons,221
increased expression of the interferon receptor subunit IFNAR2 reduced the odds of severe Covid-19 with222
Mendelian randomisation discovery p = 0.0043 (7 tests); replication p = 0.0066 (1 test). Within the assump-223
tions of Mendelian randomisation, this represents evidence for a protective role for IFNAR2 in Covid-19. We224
deemed this gene to be therapeutically-informative a priori because it is a target for exogenous interferon225
treatment. with fatal sequelae from live-attenuated measles virus in humans33,34 and with influenza in mice.35226
The variant rs10735079 (chr12, p = 1.65 × 10-8) lies in the oligoadenylate synthetase (OAS) gene clus-227
ter (OAS1, OAS2 and OAS3; Figure 1). TWAS also (Figure 3) detects significant associations in these228
genes(Figure 3). OAS genes are inducible by type I interferons. These genes encode enzymes which acti-229
vate an effector enzyme, RNAse L, which degrades double-stranded RNA,36 a replication intermediate of230
coronaviruses.37 OAS1 variants were implicated in susceptibility to SARS-CoV in candidate gene association231
studies in Vietnam38 and China.39232
The association in 19p13.3 (rs2109069, p = 3.98 × 1012) is an intronic variant in the gene encoding dipeptidyl233
peptidase 9 (DPP9). Variants in this locus are associated with idiopathic pulmonary fibrosis40 and interstitial234
lung disease.41 DPP9 encodes a serine protease with diverse intracellular functions, including cleavage of the235
key antiviral signalling mediator CXCL10,42 and plays a key role in antigen presentation.43236
Since opportunities for therapeutic intervention, particularly experimental therapy, are more abundant in237
later, more severe disease, it is important that our results also reveal genes that may act to drive inflammatory238
organ injury. TYK2 is one of 4 gene products listed in the druggable genome Targets Central Resource239
Database44 as a target for baricitinib, one of the nine candidate drugs we used in the creation of our a240
priori target list (Supplementary Table 1). However, since we did not a priori include TYK2 on the final241
set of genes for focused Mendelian randomisation, we use a significance threshold corrected for the full set of242
comparisons: discovery p = 0.00049 (4614 tests); replication p = 0.0022 (9 tests).243
We replicate the finding of Ellinghaus et al. at 3p21.31.11 The extremely small p-value at this locus (p=4.77244
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× 10-30) may reflect the strength of the signal, the large size of our study, our focus on extreme severity.245
The 3p21.31 locus is populated by a number of genes with mechanisms of action that could plausibly explain246
an association. Our systematic review and meta-analysis of experimental data on betacoronavirus infection247
from other sources provides moderate biological support for FYCO1, although the additional information248
comes mostly from in vitro model systems.45249
TWAS results show that variants in this region confer genome-wide significant differences in predicted ex-250
pression of CXCR6, CCR2 and CCR3 (Supplementary Information). Association with critical illness for251
genotype-inferred CCR2 (CC-chemokine receptor 2) expression is particularly strong in lung tissue(Figure 3).252
CCR2 promotes monocyte/macrophage chemotaxis towards sites of inflammation, and there is increased ex-253
pression of the canonical ligand for CCR2, monocyte chemoattractant protein (MCP-1), in bronchoalveolar254
lavage fluid from the lungs of Covid-19 patients during mechanical ventilation.46 Circulating MCP-1 concen-255
trations are associated with more severe disease.47 Anti-CCR2 monoclonal antibody therapy in treatment of256
rheumatoid arthritis is safe.48257
The ABO locus was also previously associated with Covid-19,11 but was not significant in our study (smallest258
p=1.30 × 10-3, chr9:136115876; Supplementary Information). This does not rule out the possibility of a true259
association, but other possible explanations include differences between case and control populations in each260
study.261
Analysis of shared heritability highlights adiposity and educational attainment: genetically increased body262
mass index (BMI) and genetically decreased educational attainment are both associated with higher risk of263
severe Covid. This does not imply a causal relationship, as a number of biases may be at play, but may264
reflect the fact that increased BMI and lower socio-economic status are strong risk factors for Covid-19,49,50265
or the fact that UK Biobank participants were disproportionately drawn from a high socio-economic status266
group.51267
There is an urgent need to deepen these findings through further studies of this type, with harmonised268
integration across multiple studies. We continue to recruit to the GenOMICC study, in the expectation that269
additional associations exist and can be detected with larger numbers of cases. Future studies using whole270
genome sequencing will add spatial resolution on the genome and better detection rare variants. Effect sizes271
are likely to be higher in GenOMICC because the cohort is strongly enriched for immediately life-threatening272
disease in patients who are either receiving invasive mechanical ventilation, or considered by the treating273
physicians to be at high risk of requiring mechanical support. With 2244 cases we have statistical power274
to detect strong effects, such as the highly-significant locus at 3p21.31, as well as moderate genome-wide275
significant findings with external replication at DPP9, OAS and IFNAR2.276
Because of the urgency of completing and reporting this work, we have drawn controls from population277
genetic studies who were genotyped using different technology from the cases. We mitigated the consequent278
risk of false-positive associations driven by genotyping errors by genotyping the majority of our subjects using279
two different methods, and by verifying significant associations using two separate control groups (100,000280
genomes and Generation Scotland). The success of these mitigations is demonstrated by robust replication281
of our top hits in external studies.282
We have discovered new and highly plausible genetic associations with critical illness in Covid-19. Some of283
these associations lead directly to potential therapeutic approaches to augment interferon signalling, antago-284
nise monocyte activation and infiltration into the lungs, or specifically target harmful inflammatory pathways.285
While this adds substantially to the biological rationale underpinning specific therapeutic approaches, each286
treatment must be tested in large-scale clinical trials before entering clinical practice.287
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Materials and methods288
Recruitment289
2,636 patients recruited to the GenOMICC study (genomicc.org) had confirmed Covid-19 according to local290
clinical testing and were deemed, in the view of the treating clinician, to require continuous cardiorespiratory291
monitoring. In UK practice this kind of monitoring is undertaken in high-dependency or intensive care292
units. An additional 134 patients were recruited through ISARIC 4C (isaric4c.net) - these individuals had293
confirmed Covid-19 according to local clinical testing and were deemed to require hospital admission. Both294
studies were approved by the appropriate research ethics committees (Scotland 15/SS/0110, England, Wales295
and Northern Ireland: 19/WM/0247). Current and previous versions of the study protocol are available at296
genomicc.org/protocol.297
Genotyping298
DNA was extracted from whole blood using Nucleon Kit (Cytiva) with the BACC3 protocol. DNA samples299
were re-suspended in 1 ml TE buffer pH 7.5 (10mM Tris-Cl pH 7.5, 1mM EDTA pH 8.0). The yield of the300
DNA was measured using Qubit and normalised to 50ng/𝜇l before genotyping.301
Genotyping was performed using the Illumina Global Screening Array v3.0 + multi-disease beadchips302
(GSAMD-24v3-0-EA) and Infinium chemistry. In summary this consists of three steps: (1) whole genome303
amplification, (2) fragmentation followed by hybridisation, and (3) single-base extension and staining. For304
each of the samples, 4 𝜇l of DNA normalised to 50ng/𝜇l was used. Each sample was interrogated on the305
arrays against 730,059 SNPs. The Arrays were imaged on an Illumina iScan platform and genotypes were306
called automatically using GenomeStudio Analysis software v2.0.3, GSAMD-24v3-0-EA_20034606_A1.bpm307
manifest and cluster file provided by manufacturer.308
In 1667 cases, genotypes and imputed variants were confirmed with Illumina NovaSeq 6000 whole genome309
sequencing. Samples were aligned to the human reference genome hg38 and variant called to GVCF stage310
on the DRAGEN pipeline (software v01.011.269.3.2.22, hardware v01.011.269) at Genomics England. Vari-311
ants were genotyped with the GATK GenotypeGVCFs tool v4.1.8.1,52 filtered to minimum depth 8X (95%312
sensitivity for heterozygous variant detection,53) merged and annotated with allele frequency with bcftools313
v1.10.2.314
Quality control315
Genotype calls were carefully examined within GenomeStudio using manufacturer and published54 recom-316
mendations, after excluding samples with low initial call rate (<90%) and reclustering the data thereafter.317
Briefly, X and Y markers calls were all visually inspected and curated if necessary, as were those for au-318
tosomal markers with minor allele frequency > 1% displaying low Gentrain score, cluster separation, and319
excess or deficit of heterozygous calls. Genotype-based sex determination was performed in GenomeStudio320
and samples excluded if not matching records expectation. Five individuals with XXY genotypes were also321
detected and excluded for downstream GWAS analyses. Genotypes were exported, in genome reference con-322
sortium human build 37 (GRCHb37) and Illumina “source” strand orientation, using the GenotypeStudio323
plink-input-report-plugin-v2-1-4. A series of filtering steps was then applied using PLINK 1.9 leaving324
2799 individuals and 479095 variants for further analyses (exclusion of samples with call rate < 95%, selection325
of variants with call rate > 99% and minor allele frequency (MAF) > 1% and final samples selection using326
a call rate > 97%).327
Kinship328
Kinship and ancestry inference were calculated following UK Biobank51 and 1M veteran program.55 First King329
2.156 was used to find duplicated individuals which have been recruited by two different routes. The analysis330
flagged 56 duplicated pairs, from which one was removed according to genotyping quality (GenomeStudio331
p50GC score or/and individual call rate). This leaves a set of 2734 unique individuals.332
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Regions of high linkage disquilibrium (LD) defined in the UK Biobank51 were excluded from the analy-333
sis, as well as SNPs with MAF<1% or missingness >1%. King 2.1 was used to construct a relation-334
ship matrix up to 3rd degree using the King command --kinship --degree 3 and then the function335
largest_independent_vertex_set() from the igraph tool[[http://igraph.sf.net]] was used to create a first336
set of unrelated individuals. Principal component analysis (PCA) was conducted with gcta 1.957 in the set337
of unrelated individuals with pruned SNPs using a window of 1000 markers, a step size of 80 markers and an338
r2 threshold of 0.1. SNPs with large weights in PC1, PC2 or PC3 were removed, keeping at least 2/3 of the339
number of pruned SNPs to keep as an input of the next round of King 2.1. The second round of King 2.1 was340
run using the SNPs with low weights in PC1, PC2 and PC3 to avoid overestimating kinship in non-european341
individuals. After this round 2718 individuals were considered unrelated up to 3rd degree.342
Genetic ancestry343
Unrelated individuals from the 1000 Genome Project dataset were calculated using the same procedure344
described above, and both datasets were merged using the common SNPs. The merged genotyped data345
was pruned with plink using a window of 1000 markers a step size of 50 and a r2 of 0.05, leaving 92K346
markers that were used to calculate the 20 first principal components with gcta 1.9. Ancestry for genomicc347
individuals was inferred using ADMIXTURE58 populations defined in 1000 genomes. When one individual348
had a probability > 80% of pertaining to one ancestry, then the individual was assigned to this ancestry,349
otherwise the individual was assigned to admix ancestry as in the 1M veteran cohort.55 According to this350
criterion there are 1818 individuals from European ancestry, 190 from African ancestry, 158 from East Asian351
ancestry, 254 from South Asian ancestry, and 301 individuals with admixed ancestry (2 or more).352
Imputation353
Genotype files were converted to plus strand and SNPs with Hardy-Weinberg Equilibrium (HWE) p-354
value<10-6 were removed. Imputation was calculated using the TOPMed reference panel.18 and results were355
given in grch38 human reference genome and plus strand. The imputed dataset was filtered for monogenic356
and low imputation quality score (r2<0.4) using BCFtools 1.9. To perform GWAS, files in VCF format were357
further filtered for r2>0.9 and converted to BGEN format using QCtools 1.3.59358
UK Biobank imputed variants with imputation score >0.9 and overlapping our set of variants (n=5,981,137)359
were extracted and merged with GenOMICC data into a single BGEN file containing cases and controls using360
QCtools 1.3.361
GWAS362
Individuals with a positive Covid-19 test or suspected Covid-19 when they were admitted in the hospital363
were included in the GWAS as cases. Related individuals to degree 3 were removed. 13 individuals with364
American ancestry were removed as the sample size provided insufficient power to perform a reliable GWAS365
for this group. The final dataset includes 2244 individuals: 1676 individuals from European ancestry, 149366
individuals from East Asian ancestry, 237 individuals from South Asian ancestry and 182 individuals from367
African ancestry (Table 1). If age or deprivation status were missing for some individuals, the value was set368
to the mean of their ancestry. GWAS were performed separately for each ancestry group.369
Tests for association between case-control status and allele dosage at individuals SNPs were performed by370
fitting logistic regression models using PLINK.60 Independent analyses were performed for each ethnic group.371
All models included sex, age, mean centered age squared, deprivation score decile of residential postcode, and372
the first 10 genomic principal components as covariates.373
Genomic principal components were computed on the combined sample of all UK Biobank and GenOMICC374
participants. Specifically, 456,750 genetic variants were identified which were shared between the variants375
contained in the called genotypes in the GenOMICC dataset and imputed UK Biobank genotypes, which376
had an information score above 0.95 and a minor allele frequency above 1%. After merging genotypes at377
these variants, variants were removed which had a minor allele frequency below 2.5%, a missingness rate378
above 1.5%, showed departure from Hardy-Weinberg equilibrium with a p value below 10-50, or which were379
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within previously identified regions of high linkage disequilibrium within UK Biobank. After LD-pruning380
of the remaining variants to a maximum r2 of 0.01 based on a 1000 variant window moving in 50 variants381
steps, using the PLINK indep-pairwise command and yielding 13,782 SNPs, the leading 20 genomic principal382
components were computed using FlashPCA2.61383
GWAS results were filtered for MAF>0.01, variant genotyping rate > 0.99 and HWE p-value > 10-50 for each384
ethnicity. An extra filter was added to avoid bias for using a different genotyping method and imputation385
panel between controls and cases. This could not be controlled for using regression because all cases and386
all controls were genotyped using different methods. MAF for each ancestry were compared between UK387
Biobank and gnomAD hg38 downloaded in August 2020.62 SNPs were were removed from the GWAS results388
specifically for each ethnicity following these two rules: (a) In SNPs with MAF > 10% in gnomAD, an absolute389
difference of 5% between gnomAD and UK biobank controls MAF (b) In SNPs with MAF <10% in gnomAD,390
a difference > 25% gnomAD MAF, between UK Biobank controls and gnomAD. To calculate differences391
between UK Biobank European individuals and gnomAD allele frequencies, non Finnish-europeans gnomAD392
allele frequencues were used, as European UK Biobank controls are mainly non-Finnish.393
Deprivation score The UK Data Service provides measures of deprivation based on Census Data and394
generated per postcode. The latest version of the Deprivation Scores were published in 2017 and are based395
on the 2011 census. Since only partial postcodes were available for most samples we were unable to use these396
indices directly. However, we generated an approximation to the scores by calculating an average weighted397
by population count across the top-level postcode areas.398
The initial input file was part of the aggregated census data identified by DOI:10.5257/census/aggregate-399
2011-2.400
Specifically the postcode data were downloaded from:401
http://s3-eu-west-1.amazonaws.com/statistics.digitalresources.jisc.ac.uk/dkan/files/Postcode_Counts_and402
_Deprivation_Ranks/postcodes.zip403
Population count and deprivation score for each published postcode were extracted and weighted average404
score calculated for each top-level postcode. We further categorised each top-level postcode score into decile405
and quintile bins for more coarse-grained analyses.406
Whole Genome Sequencing407
Whole Genome Sequencing (WGS) gVCF files were obtained for the 1667 individuals for which we had whole408
genome sequence data. Variants overlapping the positions of the imputed variants were called using GATk409
and variants with depth<8 (the minimum depth for which 95% coverage can be expected) were filtered.410
Individual VCF files were joined in a multi-sample VCF file for comparison with imputed variants. 1613411
of these 1667 were used in the final GWAS. Samples were filtered and variants annotaed using bcftools 1.9.412
VCF files obtained from imputation were processed in an identical manner. Alternative allele frequency was413
calculated with PLINK 2.063 for both WGS and imputed data.414
Controls415
UK Biobank416
UK Biobank participants were were considered as potential controls if they were not identified by the UK417
Biobank as outliers based on either genotyping missingness rate or heterogeneity, and their sex inferred from418
the genotypes matched their self-reported sex. For these individuals, information on sex (UKBID 31), age,419
ancestry, and residential postcode deprivation score decile was computed. Specifically, age was computed420
as age on April 1st, 2020 based on the participant’s birth month (UKBID 34) and year (UKBID 52). The421
first part of the residential postcode of participants was computed based on the participant’s home location422
(UKBID 22702 and 22704) and mapped to a deprivation score decile as previously described for GenOMICC423
participants. Ancestry was inferred as previously described for GenOMICC participants.424
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After excluding participants who had received PCR tests for Covid-19, based on information downloaded425
from the UK Biobank in August 2020, five individuals with matching inferred ancestry were sampled for each426
GenOMICC participant as controls. After sampling each control, individuals related up to 3rd degree were427
removed from the pool of potential further controls.428
Generation Scotland429
Generation Scotland: Scottish Family Health Study (hereafter referred to as Generation Scotland)430
is a population-based cohort of 24 084 participants sampled from five regional centers across Scot-431
land(www.generationscotland.org).64 A large subset of participants were genotyped using either Illumina432
HumanOmniExpressExome-8v1_A or v1-2, and 20 032 passed QC criteria previously described.65,66433
Genotype imputation using the TOPMed reference panel was recently performed (freeze 5b) using Minimac4434
v1.0 on the University of Michigan serverhttps://imputationserver.sph.umich.edu.67 Imputation data from435
unrelated (genomic sharing identical by descent estimated using PLINK1.9 < 5%) participants were used as436
control genotypes in a GWAS using GenOMICC cases of European ancestry, for quality check purpose of437
associated variants.438
Replication439
GenOMICC EUR loci were defined by clumping function of PLINK 1.9 and clumping parameters r2 0.1440
pval=5e-8 and pval2 0.01, and distance to the nearest gene was calculated using ENSEMBL grch37 gene441
annotation.442
No GWAS has been reported of critical illness or mortality in Covid-19. As a surrogate, to provide some443
replication for our findings, replication analyses were performed using Host Genetics Initiative build 37,444
version 2 (July 2020) B2 (hospitalised Covid-19 vs population) v2 GWAS. Summary statistics were used from445
the full analysis, including all cohorts and GWAS without UK Biobank, to avoid sample overlap. Replication446
p-value was set to 0.05/𝑛, where 𝑛 is the number of loci significant in the discovery.447
Post-GWAS analyses448
TWAS449
We performed transcriptome-wide association using the MetaXcan framework25 and the GTExv8 eQTL450
MASHR-M models available for download (http://predictdb.org/). First GWAS results were harmonised,451
lifted over to hg38 and linked to 1000 Genomes reference panel using GWAS tools https://github.com/hakyi452
mlab/summary-gwas-imputation/wiki/GWAS-Harmonization-And-Imputation. TWAS for whole blood and453
lung were calculated using GWAS summary statistics for the European population GWAS and S-PrediXcan.454
Resulting p-values were corrected using the Bonferroni correction to find significant gene associations.455
Mendelian randomisation456
Two-sample Summary data based Mendelian randomisation [PMID 27019110] was performed using the re-457
sults of GenOMICC and the Genotype-Tissue expression project, GTEx v7 (chosen in preference to v8458
because of the availability of pre-computed data for SMR/HEIDI),[PMID 29022597] with Generation Scot-459
land [PMID 22786799; PMID 17014726] forming a linkage disequilibrium reference. GenOMICC results460
from those of European ancestry were used as the outcome; and GTEx (v7) whole blood expression re-461
sults as the exposure. Data pertaining to GTEx v7 chosen were downloaded from the GTEx portal -462
https://gtexportal.org/ (accessed 20 Feb 2020, 05 Apr 2020, and 04 Jul 2020), and SMR/HEIDI from463
https://cnsgenomics.com/software/smr/ (accessed 03 Jul 2020). Analyses were conducted using Python464
3.7.3 and SMR/HEIDI v1.03. An LD reference was created using data from the population-based Genera-465
tion Scotland cohort (used with permission; described previously [PMID 28270201]): from a random set of466
5,000 individuals, using Plink v1.9 (www.cog-genomics.org/plink/1.9/), a set of individuals with a genomic467
relatedness cutoff < 0.01 was extracted; 2,778 individuals remained in the final set. All data used for the468
SMR/HEIDI analyses were limited to autosomal biallelic SNPs: 4,264,462 variants remained in the final469
merged dataset.470
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Significant (as per GTEx v7; nominal p-value below nominal p-value threshold) local (distance to transcrip-471
tional start site < 1Mb) eQTL from GTEx v7 whole blood for protein coding genes (as per GENCODE v19)472
with a MAF > 0.01 (GTEx v7 and GenOMICC) were considered as potential instrumental variables. Per473
variant, we first selected the Ensembl gene ID to which it was most strongly associated (so as to ensure that474
each variant can only be considered as an instrument for the gene to which it is most strongly associated)475
followed by selecting the variant to which each Ensembl gene ID was most strongly associated. Instruments476
were available for 4,614 unique Ensembl gene IDs.477
Results were assessed based upon a list of genes selected a priori as of interest (Supplementary Table 1),478
and together as a whole. Partial replication of Bonferroni-corrected significant results was attempted in479
the results of COVID19-Host Genetics Initiative - https://www.covid19hg.org/ - with UK Biobank excluded480
(accessed 21 Sep 2020). Hospitalized covid vs. population (ANA_B2_V2) was selected as the phenotype481
most similar to our own, and therefore the most appropriate for use as a replication cohort. This is not482
a complete replication - due to the repeated use of GTEX v7 Whole Blood results in both analyses - yet483
remains informative as to the strength of assoiation between the genetic variant and COVID19, with a484
consistent Mendelian Randomisation effect-size estimate.485
Gene-level486
Gene-level burden of significance in the EUR ancestry group result was calculated using MAGMA v1.08.68487
SNPs were annotated to genes by mapping based on genomic location. SNPs were assigned to a gene if the488
SNPs location is within 5 kb up- or down-stream of the gene region (defined as the transcription start site489
to transcription stop site). The MAGMA SNP-wise mean method was applied which utilises the sum of490
squared SNP Z-statistics as the test statistic. The 1000 Genomes Project European reference panel was used491
to estimate LD between SNPs.492
Auxiliary files were downloaded from https://ctg.cncr.nl/software/magma on 1st September 2020. Gene493
location files for protein-coding genes were obtained from NCBI (ftp.ncbi.nlm.nih.gov):494
gene/DATA/GENE_INFO/Mammalia/Homo_sapiens.gene_info.gz495
on 29/04/2015, and from:496
genomes/Homo_sapiens/ARCHIVE/ANNOTATION_RELEASE.105/mapview/seq_gene.md.gz497
on 25/05/2016.498
The reference data files used to estimate LD are derived from Phase 3 of the 1000 Genomes Project.499
Competitive gene set enrichment analysis was conducted in MAGMA using a regression model that ac-500
counts for gene-gene correlations, to reduce bias resulting from clustering of functionally similar genes on the501
genome.68 Gene sets were queried from the databases KEGG 2019, Reactome 2016, GO Biological Process502
2018, Biocarta 2016 and WikiPathways 2019. The Benjamini-Hochberg procedure was used to control false503
discovery rate (<0.05).504
Meta-analysis by information content (MAIC)505
Multiple in vitro and in vivo studies have identified key host genes that either directly interact with SARS-506
CoV-2, or define the host response to SARS-CoV-2. We have previously reported a systematic review of507
these studies.45 In order to put the new associations from this GWAS into context, we performed a data-508
driven meta-analysis of gene-level results combined with pre-existing biological data using meta-analysis by509
information content (MAIC).69 Briefly, MAIC combines experimental results from diverse sources in the form510
of ranked or unranked gene lists. The algorithm assigns a weighting to each input gene list, derived from the511
degree of overlap with other input lists. Each gene is then assigned a score calculated from the weightings for512
each gene list on which it appears. This process is repeated iteratively until all scores converge on a stable513
value. In order to prevent a single type of experiment from unduly biasing the results, input gene lists are514
assigned to categories, and a rule applied that only one weighting from each category can contribute to the515
score for any given gene.516
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Tissue and functional genomic enrichment517
We downloaded the mean gene expression data summarised from RNA sequencing by the GTEx project518
(https://gtexportal.org/). The GTEx v7 data contain gene expressions of 19,791 genes in 48 human tissues.519
Gene expression values were normalized to numbers of transcripts per million reads (TPM). To measure the520
expression specificity of each gene in each tissue, each gene expression specificity was defined as the propor-521
tion of its expression in each tissue among all the tissues, i.e., a value ranging between 0 and 1. SNPs within522
the 10% most specifically expressed genes in each tissue were annotated for subsequent testing of heritability523
enrichment. For functional genomic enrichment analysis, we considered the inbuilt primary functional anno-524
tations v2.2 provided in the ldsc software (https://alkesgroup.broadinstitute.org/LDSCORE/) to annotated525
the SNPs.526
With the annotated SNPs, we used stratified LD score regression (S-LDSC)70 to test whether any human527
tissue or specific functional genomic feature is associated with sereve Covid-19. Our GWAS summary statistics528
were harmonized by the munge_sumstats.py procedure in ldsc. LD scores of HapMap3 SNPs (MHC region529
excluded) for gene annotations in each tissue were computed using a 1-cM window. The enrichment score530
was defined as the proportion of heritability captured by the annotated SNPs divided by the proportion of531
SNPs annotated.532
Testing genetic correlations with other phenotypes533
We applied both the LD score regression (LDSC)71 and high-definition likelihood (HDL)26 methods to eval-534
uate the genetic correlations between Severe Covid-19 and 818 GWASed phenotypes stored on LD-Hub.72535
GWAS summary statistics were harmonized by the munge_sumstats.py procedure in the ldsc software. In536
the HDL analysis, we estimated the SNP-based narrow-sense heritability for each phenotype, and for the 818537
complex traits GWASs, those with SNPs less than 90% overlap with the HDL reference panel were removed.538
Genome build539
Results are presented using Genome Reference Consortium Human Build 37. Imputed genotypes and whole-540
genome sequence data were lifted over from Genome Reference Consortium Human Build 38 using Picard541
liftoverVCF mode from GATK 4.0 which is based on the UCSC liftover tool(chain file obtained from ftp:542
//ftp.ensembl.org/pub/assembly_mapping/homo_sapiens/GRCh38_to_GRCh37.chain.gz.73543
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